Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fert

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue ® fer

The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval a

FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent b

Gainers ZeroStack (NASDAQ:ZSTK) stock increased by 440.2% to $9.94 during Wednesday's regular s

Femasys (NASDAQ:FEMY) reported quarterly losses of $(1.08) per share which beat the analyst consensu

Maxim Group analyst Jason McCarthy maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the pric

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility

-- New U.S. and international patents complement existing delivery system patents, extending global

 Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and

-- Potential proceeds would be received upon full cash exercise of warrants --  ATLANTA, Aug. 07, 20

Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re

ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovat

Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgi

-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- Ne

-- With fertility rates at historic lows, Femasys advances access to early infertility care through

The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shi

-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlin

CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) ar

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.06) per share which beat the analyst consensu

-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surg

Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating

ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovat

-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven t

-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility trea

-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility trea

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical perman

Femasys Inc. (NASDAQ: FEMY) ("Femasys" or the "Company"), a leading biomedical innov

Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permane

Partnership enables broader adoption of FemaSeed through a trusted community health provider serving

Femasys Inc. (NASDAQ: FEMY - Get Free Report) shares traded up 0.1% during trading on Monday. The st

Response Genetics (OTCMKTS:RGDXQ - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) are

-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support f

-- Innovative single-device solution integrates proven FemVue and FemChec ® technologies to support

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announ

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”),

Laidlaw & Co. analyst Yale Jen initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.10) per share which beat the analyst consensu